Long Non-coding RNA-SNHG7 Acts As a Target of MiR-34a to Increase GALNT7 Level and Regulate PI3K/Akt/mTOR Pathway in Colorectal Cancer Progression

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2018 Jul 5

PMID 29970122

Citations 104

Authors

Yang Li

Changqian Zeng

Jialei Hu

Yue Pan

Yujia Shan

Bing Liu

Li Jia

Affiliations

Soon will be listed here.

Abstract

Background: Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. The long non-coding RNAs (lncRNAs), emerging as key molecules in human malignancy, has become one of the hot topics in RNA biology. Aberrant O-glycosylation is a well-described hallmark of many cancers. GALNT7 acts as a glycosyltransferase in protein O-glycosylation, involving in the occurrence and development of CRC.

Methods: The microarrays were used to survey the lncRNA and mRNA expression profiles of primary CRC cell line SW480 and metastatic CRC cell line SW620. Cell proliferation, migration, invasion, and apoptosis were assayed. Xenograft mouse models were used to determine the role of lncRNA-SNHG7 in CRC in vivo. In addition, CNC analysis and competing endogenous analysis were used to detect differential SNHG7 and relational miRNAs expression in CRC cell lines.

Results: SNHG7 expression showed a high fold (SW620/SW480) in CRC microarrays. The CRC patients with high expression of SNHG7 had a significantly poor prognosis. Furthermore, SNHG7 promoted CRC cell proliferation, metastasis, mediated cell cycle, and inhibited apoptosis. SNHG7 and GALNT7 were observed for co-expression by CNC analysis, and a negative correlation of SNHG7 and miR-34a were found by competing endogenous RNA (ceRNA) analysis. Further results indicated that SNHG7 facilitated the proliferation and metastasis as a competing endogenous RNA to regulate GALNT7 expression by sponging miR-34a in CRC cell lines. SNHG7 also played the oncogenic role in regulating PI3K/Akt/mTOR pathway by competing endogenous miR-34a and GALNT7.

Conclusion: The CRC-related SNHG7 and miR-34a might be implicated in CRC progression via GALNT7, suggesting the potential usage of SNHG7/miR-34a/GALNT7 axis in CRC treatment.

Citing Articles

Mechanism of action and new developments in the study of curcumin in the treatment of osteoarthritis: a narrative review.

Yang Y, Li J, Zhang J, Zhang K, Zhang A, Li P Inflammopharmacology. 2025; .

PMID: 40009345 DOI: 10.1007/s10787-025-01665-6.

Interplay between lncRNAs and the PI3K/AKT signaling pathway in the progression of digestive system neoplasms (Review).

Zhang X, Shi L, Xing M, Li C, Ma F, Ma Y Int J Mol Med. 2024; 55(1).

PMID: 39513614 PMC: 11573320. DOI: 10.3892/ijmm.2024.5456.

Correlation of SNHG7 and BGL3 expression in patients with de novo acute myeloid leukemia; novel insights into lncRNA effect in PI3K signaling context in AML pathogenesis.

Hassani S, Rostami P, Pourtavakol M, Karamashtiani A, Sayyadi M Biochem Biophys Rep. 2024; 40:101850.

PMID: 39469045 PMC: 11513491. DOI: 10.1016/j.bbrep.2024.101850.

Dong Y, He Y, Geng Y, Wei M, Zhou X, Lian J Cancer Cell Int. 2024; 24(1):328.

PMID: 39342235 PMC: 11439232. DOI: 10.1186/s12935-024-03503-1.

Unique miRNA Expression Profile in MSI- and EMAST-Unstable Sporadic Colon Cancer.

Marinovic S, Derfi K, Skrtic A, Poljak M, Kapitanovic S Genes (Basel). 2024; 15(8).

PMID: 39202367 PMC: 11353743. DOI: 10.3390/genes15081007.

References

Khoury G, Baliban R, Floudas C . Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Sci Rep. 2011; 1. PMC: 3201773. DOI: 10.1038/srep00090. View

Ho W, Chou C, Jeng Y, Lu M, Yang Y, Jou S . GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget. 2014; 5(23):12247-59. PMC: 4322969. DOI: 10.18632/oncotarget.2627. View

Shan S, Fang L, Shatseva T, Rutnam Z, Yang X, Du W . Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci. 2013; 126(Pt 6):1517-30. DOI: 10.1242/jcs.122895. View

Cheng S, Huang Liu R, Sheu J, Chen S, Sinchaikul S, Tsay G . Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006; 29(4):655-69. DOI: 10.1248/bpb.29.655. View

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A . Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 2013; 109(2):472-81. PMC: 3721383. DOI: 10.1038/bjc.2013.331. View

Qu J, Li M, Zhong W, Hu C . Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med. 2016; 8(10):17110-6. PMC: 4694204. View

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

10.

Zhou M, Zhong L, Xu W, Sun Y, Zhang Z, Zhao H . Discovery of potential prognostic long non-coding RNA biomarkers for predicting the risk of tumor recurrence of breast cancer patients. Sci Rep. 2016; 6:31038. PMC: 4977495. DOI: 10.1038/srep31038. View

11.

Li S, Xu H, Yu Y, He J, Wang Z, Xu Y . LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016; 7(27):42431-42446. PMC: 5173146. DOI: 10.18632/oncotarget.9883. View

12.

Liu Q, Guo X, Que S, Yang X, Fan H, Liu M . LncRNA RSU1P2 contributes to tumorigenesis by acting as a ceRNA against let-7a in cervical cancer cells. Oncotarget. 2016; 8(27):43768-43781. PMC: 5546439. DOI: 10.18632/oncotarget.10844. View

13.

Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y . Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013; 6:37. PMC: 3693878. DOI: 10.1186/1756-8722-6-37. View

14.

Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H . A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015; 35(3):1385-8. View

15.

Xiang J, Yin Q, Chen T, Zhang Y, Zhang X, Wu Z . Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014; 24(5):513-31. PMC: 4011346. DOI: 10.1038/cr.2014.35. View

16.

Zhang R, Lahens N, Ballance H, Hughes M, Hogenesch J . A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014; 111(45):16219-24. PMC: 4234565. DOI: 10.1073/pnas.1408886111. View

17.

Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

18.

Akinleye A, Avvaru P, Furqan M, Song Y, Liu D . Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013; 6(1):88. PMC: 3843585. DOI: 10.1186/1756-8722-6-88. View

19.

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

20.

Taniuchi K, Cerny R, Tanouchi A, Kohno K, Kotani N, Honke K . Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 2011; 30(49):4843-54. PMC: 3373266. DOI: 10.1038/onc.2011.194. View